The vertebral 3'-deoxy-3'-
Adult
Aged
Antineoplastic Agents
/ adverse effects
Cell Proliferation
Chemoradiotherapy
/ adverse effects
Female
Fluorine Radioisotopes
/ metabolism
Humans
Lung Neoplasms
/ metabolism
Male
Middle Aged
Platinum
/ administration & dosage
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
/ methods
ROC Curve
Retrospective Studies
Sensitivity and Specificity
Tomography, X-Ray Computed
/ methods
Chemotherapy
Lumbar vertebrae
Lung cancer
Positron emission tomography (PET)
Thymidine
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
26
09
2018
accepted:
13
03
2019
revised:
28
02
2019
pubmed:
12
4
2019
medline:
7
9
2019
entrez:
12
4
2019
Statut:
ppublish
Résumé
Although hematological toxicities (HT) are the leading adverse events of systemic chemotherapy, the estimation of severe HT is challenging. Recently, 3'-deoxy-3'-[ In this Institutional Review Board-approved retrospective study, 50 patients with primary lung cancer underwent Severe HT (grade 3/4) was observed in 40.0% of patients during the first cycle. The ROC curve analyses revealed that the TVP/BSA of L4 was the most discriminative parameter among PET parameters for the prediction of severe HT. The multivariate logistic regression analysis revealed the TVP/BSA of L4 (odds ratio [OR], 0.94; p = 0.0036) and the frequency of the grade 3/4 hematological toxicity in previous clinical trials (OR, 1.03; p = 0.023) were independent predictors. Furthermore, the sensitivity, specificity, and accuracy of the TVP/BSA of L4 cut-off of 68.7 to predict grade 3/4 HT were 80.0%, 86.7%, and 84.0%, respectively. A low TVP/BSA of L4 (< 68.7) as a binary variable was a significant indicator of severe HT (OR, 26.0; p = 0.000026). The low Trial registration: UMIN000027540 KEY POINTS: • The vertebral
Identifiants
pubmed: 30972546
doi: 10.1007/s00330-019-06161-4
pii: 10.1007/s00330-019-06161-4
doi:
Substances chimiques
Antineoplastic Agents
0
Fluorine Radioisotopes
0
Platinum
49DFR088MY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3908-3917Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology (JP)
ID : JP22790752
Organisme : University of Fukui Hospital
ID : Scientific research program "Seeds of Advanced Medicine"
Références
Cancer Res. 2016 Dec 15;76(24):7089-7095
pubmed: 27923827
J Clin Oncol. 2009 May 20;27(15):2530-5
pubmed: 19349543
Ann Oncol. 2007 Feb;18(2):317-23
pubmed: 17079694
J Clin Oncol. 2013 Aug 20;31(24):3004-11
pubmed: 23835708
Ann Oncol. 2009 Mar;20(3):513-9
pubmed: 19139177
J Nucl Med. 2014 Jul;55(7):1075-80
pubmed: 24868108
Br J Cancer. 2007 Jul 16;97(2):162-9
pubmed: 17579629
Nucl Med Biol. 2010 May;37(4):433-8
pubmed: 20447554
Ann Oncol. 2015 Jul;26(7):1401-8
pubmed: 25908605
Skeletal Radiol. 1985;14(1):10-9
pubmed: 3895447
J Clin Oncol. 2009 Jun 10;27(17):2758-65
pubmed: 19403886
J Nucl Med. 2015 Jun;56(6):945-50
pubmed: 25766892
Cancer Res. 2003 May 15;63(10):2681-7
pubmed: 12750297
Radiology. 1988 Sep;168(3):679-93
pubmed: 3043546
J Clin Oncol. 2013 Dec 1;31(34):4349-57
pubmed: 24145346
Eur J Cancer Care (Engl). 2010 Sep;19(5):648-55
pubmed: 20088918
Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):888-93
pubmed: 21300484
J Thorac Oncol. 2015 Jan;10(1):134-42
pubmed: 25371077
Br J Haematol. 2009 Mar;144(5):677-85
pubmed: 19055662
Indian J Hematol Blood Transfus. 2017 Dec;33(4):470-476
pubmed: 29075056
Support Care Cancer. 2018 Nov;26(11):3691-3699
pubmed: 29736867
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Eur J Cancer. 2012 Dec;48(18):3499-513
pubmed: 22658807
J Clin Oncol. 2010 Dec 20;28(36):5240-6
pubmed: 21079147
Eur J Cancer. 2002 Jul;38(11):1466-73
pubmed: 12110492
BMC Cancer. 2014 Mar 19;14:201
pubmed: 24641830
Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1610-6
pubmed: 17530250
J Nucl Med. 2017 Oct;58(10):1603-1608
pubmed: 28360204
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685